FEATURED STORY

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The company is currently testing its lead drug candidate, CRV431, in Phase 1 trials, and recently submitted an IND to the FDA for the treatment of NASH, which complements Hepion’s current IND for the HBV indication. In this interview with BioTuesdays, Dr. Robert Foster discusses NASH, data the company has generated to-date, and its clinical development plans for CRV431.

Read the Story

SELECT BRIEFS

NASDAQ:HEPA

Hepion Pharmaceuticals

FDA clears Hepion Pharma’s IND for CRV431 for the treatment of NASH

NASDAQ:MYOV

Myovant Sciences

Myovant's relugolix meets primary endpoint in Phase 3 uterine fibroid trial

TSXV:TLT; OTCQB:TLTFF

Theralase Technologies

In pact for U.S. clinical sites for Phase 2 NMIBC trial

TSX:ZENA

Zenabis

increases licensed capacity by more than 40% with substantial completion of Zenabis Atholville

More Briefs

Wall Street News

About BioTuesdays

BioTuesdays was created in 2009 by Kilmer Lucas, a leading healthcare-only investor relations firm. Employing a unique "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized IR & PR programs for its drug development, medical device, cell therapy, diagnostics and healthcare services clients. But, most of BioTuesdays' content isn't client-driven. Rather, our mission is to give as many great healthcare companies and their stories as much exposure as we can.

Want to be featured in BioTuesdays? Get in touch with us.

Copyright © 2019 Kilmer Lucas, All rights reserved.
You are receiving this email because you signed up for the BioTuesdays newsletter.
Privacy Policy

BioTuesdays
PO Box 297
Carlisle, ON L0R 1H0

subscribe | unsubscribe | update your preferences